These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26224332)

  • 41. Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine.
    Figurski MJ; Nawrocki A; Pescovitz MD; Bouw R; Shaw LM
    Ther Drug Monit; 2008 Aug; 30(4):445-55. PubMed ID: 18641543
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Limited sampling strategy for estimating individual exposure of tacrolimus in pediatric kidney transplant patients.
    Zhao W; Fakhoury M; Baudouin V; Maisin A; Deschênes G; Jacqz-Aigrain E
    Ther Drug Monit; 2011 Dec; 33(6):681-7. PubMed ID: 22011724
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
    Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
    J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
    Capone D; Tarantino G; Kadilli I; Polichetti G; Basile V; Federico S; Sabbatini M
    Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience.
    Singh D; Kiberd B; Belitsky P; Fraser A; Balbontin F; Lawen J
    Transplant Proc; 2004 Mar; 36(2 Suppl):414S-419S. PubMed ID: 15041377
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Experience with therapeutic drug monitoring of cyclosporine.
    Abendroth D
    Transplant Proc; 2004 Mar; 36(2 Suppl):426S-429S. PubMed ID: 15041379
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic study and limited sampling strategy of cyclosporine in Japanese heart transplant recipients.
    Wada K; Takada M; Ueda T; Ochi H; Morishita H; Hanatani A; Nakatani T
    Circ J; 2006 Oct; 70(10):1307-11. PubMed ID: 16998264
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients.
    Cremers SC; Scholten EM; Schoemaker RC; Lentjes EG; Vermeij P; Paul LC; den Hartigh J; de Fijter JW
    Nephrol Dial Transplant; 2003 Jun; 18(6):1201-8. PubMed ID: 12748356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New strategies of cyclosporine monitoring in heart transplantation: initial results.
    Arizón del Prado JM; Aumente Rubio MD; Cárdenas Aranzana M; López Malo de Molina MD; Segura Saint-Gerons J; López Granados A; Rodríguez Esteban E; Ruiz Ortiz M; Romo Peñas E; Muñoz Carvajal I; González Rodríguez JR; Segura Saint-Gerons C; Vallés Belsué F; Concha Ruiz M
    Transplant Proc; 2003 Aug; 35(5):1984-7. PubMed ID: 12962870
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is the lower cyclosporine concentration at 2 hours after dosing safe in kidney transplant recipients?
    Einollahi B; Rostami Z; Kalantar E; Lessan-Pezeshki M; Pourfarziani V; Nemati E
    Transplant Proc; 2011 Mar; 43(2):488-90. PubMed ID: 21440741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplant patients.
    Baraldo M; Isola M; Feruglio MT; Francesconi A; Franceschi L; Tursi V; Livi U; Furlanut M
    Transplant Proc; 2005 Jun; 37(5):2240-3. PubMed ID: 15964387
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Usefulness of two-point AUC(0-4) monitoring in maintenance renal transplant patients.
    Uchida K; Tominaga Y; Haba T; Katayama A; Sato T; Matsuoka S; Goto N; Kimata T; Takeda A; Morozumi K; Takagi H; Kobayashi T; Yokoyama I; Nakao A
    Transplant Proc; 2001; 33(7-8):3128-30. PubMed ID: 11750345
    [No Abstract]   [Full Text] [Related]  

  • 56. Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation.
    Monchaud C; Rousseau A; Leger F; David OJ; Debord J; Dantoine T; Marquet P
    Eur J Clin Pharmacol; 2003 Apr; 58(12):813-20. PubMed ID: 12698308
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.
    Loichot C; Bentue-Ferrer D; Bernard N; Bonardet A; Boulieu R; Kergueris MF; Paintaud G; Peytavin G; Simon N; Marquet P;
    Fundam Clin Pharmacol; 2006 Feb; 20(1):91-6. PubMed ID: 16448399
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study.
    Iversen M; Nilsson F; Sipponen J; Eiskjaer H; Mared L; Bergan S; Nyström U; Fagertun HE; Solbu D; Simonsen S
    J Heart Lung Transplant; 2009 Sep; 28(9):919-26. PubMed ID: 19716045
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Greater variability of dose-corrected cyclosporine C2 concentrations in renal recipients with acute rejection.
    Chueh SC; Liao CH; Lai MK
    Transplant Proc; 2003 Feb; 35(1):234-5. PubMed ID: 12591378
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation.
    Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Shibuya Y; Kato M; Takahashi M; Miura I
    J Clin Pharm Ther; 2011 Aug; 36(4):518-24. PubMed ID: 21105879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.